Kestra Medical (KMTS) director sells 15,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 Common Shares on March 17, 2026 at a weighted average price of $20.2749 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following this sale, Webster continues to hold 364,786 Common Shares directly, showing he retains a substantial equity stake in the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/17/2026	03/17/2026	S(1)		15,000	D	$20.2749(2)	364,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.0000 to $20.7709. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KMTS report for Brian Daniel Webster?

Brian Daniel Webster reported selling 15,000 Kestra Medical Common Shares in an open-market transaction. The sale occurred on March 17, 2026 and involved shares of KESTRA MEDICAL TECHNOLOGIES, LTD. common stock as disclosed in the Form 4 filing.

At what price were the 15,000 KMTS shares sold by the director?

The 15,000 KMTS shares were sold at a weighted average price of $20.2749 per share. Actual sale prices ranged between $20.0000 and $20.7709, according to the disclosure, with full breakdowns available upon request from the reporting person.

How many KMTS shares does Brian Daniel Webster hold after this sale?

After the reported sale, Brian Daniel Webster directly holds 364,786 Common Shares of Kestra Medical. This post-transaction balance indicates he maintains a significant ongoing ownership position in the company despite selling a portion of his holdings.

Was the KMTS insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transaction occurred under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such plans pre-schedule trades, suggesting the timing of this sale was set in advance rather than decided opportunistically.

What type of transaction was reported in the KMTS Form 4?

The filing reports an open-market sale of non-derivative Common Shares. The transaction is coded as an “S” sale, indicating a sale in the open market or private transaction, rather than an option exercise, grant, gift, or tax-withholding event.

Does the KMTS Form 4 mention price details beyond the average sale price?

Yes. The filing notes the Column 4 price is a weighted average, with individual trades executed between $20.0000 and $20.7709. The reporting person offers to provide the exact share counts at each price level upon request to interested parties.